A new study from Sweden's Karolinska Institutet confirms that the Human Papillomavirus (HPV) vaccine provides long-term protection against invasive cervical cancer. The research, published in The BMJ, followed nearly one million girls and women for up to 18 years. It found vaccinated individuals had a 79% lower risk of developing cervical cancer compared to those who were not vaccinated.[vaccinestoday+6]
Sustained Protection Confirmed
The extensive study analyzed data from 926,362 girls and women born between 1985 and 2001. Researchers tracked their health from January 2006 to December 2023. A key finding was that the protection offered by the HPV vaccine did not weaken over the 18-year period. This means the vaccine provides sustained defense against the virus that causes most cervical cancers.[vaccinestoday+6]
Women who received the vaccine before age 17 showed the strongest protection, with an almost 80% lower risk of cancer.Even 13 to 15 years after vaccination, their risk remained about 77% lower.Those vaccinated at 17 years or older also saw a reduced risk, showing a 37% lower chance of developing cervical cancer.[news+6]
Expert Views and Public Health Goals
Shiqiang Wu, a research assistant and doctoral student at Karolinska Institutet, highlighted the significance of the findings. "It is encouraging that the protection persists as young girls become adults and reach the ages when cervical cancer often occurs," Wu stated.He added that the study's results suggest that "no booster doses of the HPV vaccine are needed at present."[news+3]
The study also noted differences in protection based on how the vaccine was offered. Those who received the vaccine through school health services had a 72% lower risk of cervical cancer compared to older groups who had to seek vaccination outside routine programs.This emphasizes the importance of widespread vaccination programs, especially for younger populations.[news+5]
Building on Earlier Research
This latest Swedish study builds upon a landmark 2020 study, also from Sweden, published in the New England Journal of Medicine. That earlier research analyzed data from over 1.6 million women and found a nearly 90% reduction in cervical cancer incidence among girls vaccinated before age 17 over an 11-year period.The new analysis extends this follow-up to almost two decades, providing even stronger evidence of the vaccine's long-term effectiveness.[gavi+2]
The findings offer strong support for global efforts to eliminate cervical cancer. This disease affects hundreds of thousands of women worldwide each year. Experts hope high vaccination rates can significantly reduce its impact.The quadrivalent HPV vaccine was used in the study, protecting against several types of HPV.[vaccinestoday+8]
The sustained protection observed in this large study reinforces the critical role of routine HPV immunization programs in protecting future generations from cervical cancer.[gavi+3]
